CN202740213U

CN202740213U - Lacrimal passage embolus

Info

Publication number: CN202740213U
Application number: CN201220419804.1U
Authority: CN
Inventors: 邓新国
Original assignee: Zhongshan Ophthalmic Center
Current assignee: Zhongshan Ophthalmic Center
Priority date: 2012-08-22
Filing date: 2012-08-22
Publication date: 2013-02-20
Anticipated expiration: 2022-08-22

Abstract

The utility model discloses a lacrimal passage embolus. The lacrimal passage embolus comprises a lacrimal passage embolus body, wherein the lacrimal passage embolus body is a fusiform shape, two ends of the fusiform shape are small, and the middle of the fusiform shape is large; or the middle of the lacrimal passage embolus body is cylindrical, and two ends of the lacrimal passage embolus are of a blunt round shape. The surface of the lacrimal passage embolus body is provided with a plurality of axial grooves. The lacrimal passage embolus is designed into the fusiform shape, wherein the two ends of the fusiform shape are small, and the middle of the fusiform shape is large; or the middle of the lacrimal passage embolus body is cylindrical, and two ends of the lacrimal passage embolus are of a blunt round shape. The lacrimal passage embolus of the shape can be easily implanted into a lacrimal passage, can block a lacrimal ductule, and can be easily removed (by means of lacrimal passage irrigation). Material of the lacrimal passage embolus is made of titanium-nickel alloy or poly oxygen cyclohexane, wherein the lacrimal passage embolus made of the titanium-nickel alloy is a permanent lacrimal passage embolus, and the lacrimal passage embolus made of the poly oxygen cyclohexane is a lacrimal passage embolus which can be dissolved in half a year. The lacrimal passage embolus is very simple in structure, low in manufacturing cost, and capable of consumed by common people.

Description

A kind of lacrimal duct embolus

Technical field:

This utility model belongs to medical instruments field, is specifically related to a kind of lacrimal duct embolus.

Background technology:

Xerophthalmia claims again xerophthalmia, xerophthalmia, angle conjunctival xerosis (Kerstoconjunctivitis sicca, KCS) and drying property syndrome etc.Refer to the unstable and/or hypertonicity tear of the tear film that is caused by many reasons, cause ocular surface injury or immune inflammation, produce a class disease of ophthalmic uncomfortable symptom or visual disorder.Its clinical symptoms is usually expressed as sensation of dryness, foreign body sensation, pain, burn feeling, ophthalmic pruritus, blurred vision, furious, photophobia, shed tears etc.But heavy when light during dry eye symptoms, the eye dryness sense is the most obvious symptom, and when particularly drying out of doors, attention is concentrated when twinkling minimizing more obvious, and night or early morning, the xerophthalmia shape was very obvious when waking up.The severe xerophthalmia will cause conjunctiva or corneal epithelium degeneration, cornea mist-like bleary, new vessels intrusion, corneal epithelial defect, aseptic corneal ulcer and infective corneal ulcer etc., patient's xerophthalmia sx↑, the symptom such as spasm of ocular muscles can occur, can't keep one's eyes open.

In recent years, along with the development of science and technology, the use of computer, TV and air-conditioning, is worn contact lens and is abused the reason such as eye drop the ophthalmology excimer laser surgery, and xerophthalmia is the trend that increases year by year and the characteristics that become younger.But clinical common with women after young women, menopause and menopause.In 30～40 years old crowd of India, suffer from xerophthalmia greater than 20%, more than 70 years old among the crowd prevalence then up to 36.1%.In 65～84 years old crowd of the U.S., the sickness rate of xerophthalmia is 14.6%, namely has approximately 4,300,000 people to suffer from xerophthalmia.In 45～54 years old crowd of Germany, about 20% women and 15% male have the sign of angle conjunctival xerosis.In 55～72 years old 705 routine old people of 1 community of Sweden, the prevalence rate of xerophthalmia is 15%.The Japan outpatient service head people about 17% that diagnoses a disease is xerophthalmia.2009, compatriots Tian Yujing etc. showed that to the Epidemiological study of Jiangning, Shanghai street 20 years old and above crowd's xerophthalmia the prevalence of xerophthalmia is 30.05%, and wherein the male is 24.11%, and the women is 33.78%.Xerophthalmia is becoming harm health of people and a kind of disease of quality of life.

The cause of disease or the inducement of xerophthalmia mainly contain: 1, environmentally hazardous property xerophthalmia changes, does not have enough sleep etc. such as telecomputer, air pollution, conversion in season, living environment; 2, meibomian gland dysfunction xerophthalmia will cause lipid adacrya or vapo(u)rability to cross the strong type xerophthalmia; 3, autoimmunity xerophthalmia comprises constitutional and Secondary cases dry syndrome; 4, operation property xerophthalmia, excimer laser surgery and ophthalmologic operation; 5, traumatic xerophthalmia mainly comprises physics or the chemical injury of conjunctiva and cornea; 6, Drug xerophthalmia mainly is to have used the medicine that suppresses or affect lacrimal secretion; 7, the xerophthalmia relevant with age or sex; 8, the xerophthalmia due to the conjunctiva inflammation.

The treatment xerophthalmia mainly contains: 1, eliminate the cause of disease; 2, the tear composition method of substitution; 3, control inflammation; 4, obstructed lacrimal passage; 5, promote lacrimal secretion; 6, reduce tear evaporation; 7, other treatment is as replenishing the androgen treatment; 8, operative treatment.

Wherein utilize obstructed lacrimal passage treatment xerophthalmia, adopt namely that Punctual plugs blocks that lacrimal ductule is in the at present treatment, severe xerophthalmia effective method comparatively.Its cardinal principle is to stop up the discharge that lacrimal ductule stops tear with embolus, prolongs self tear in the time of staying of eye table, moistens, nutrition eye table organization, recovers and keep the normal configuration of a table organization.In addition, obstructed lacrimal passage can increase the eye drop medicine in the time of staying of eye table, increases the bioavailability of medicine and the curative effect of medicine.

At present, being used for clinical lacrimal duct embolus mainly divides permanent and degradability progressively.The thermal denaturation lacrimal passage thromboembolism of permanent embolus such as Smart plug is bar-shaped, and Main Ingredients and Appearance is hydrophobic acrylic acid's ester, and when putting it into lacrimal passage, Smart plug embolus is pucker ﹠ bloat automatically, stops up lacrimal ductule.Although the effect of embolization of Smart plug embolus is better, it is expensive, and ruck is difficult to bear.In addition, after Smart plug lacrimal duct embolus is put into lacrimal ductule, be difficult to detect its position and existence, need to use high-frequency ultrasound diagnosis, general hospital does not have this equipment.There is expensive shortcoming equally in the permanent Punctal plug embolus of fCI prepackage type Painless of France, because the part of this embolus is exposed to outside the puncta, therefore, should select the suitable patient of puncta shape that this puncta embolus could be installed, and exist embolus to come off easily and the side effect of exciting eye table.And some degradation-type lacrimal duct embolus progressively, such as the lacrimal duct embolus made from artificial suture, half a year degradable, can play medium-term and long-term therapeutical effect, its Main Ingredients and Appearance is poly-to the oxygen cyclohexane extraction, because it is shaped as cylindrically, puts into lacrimal passage, its sharp keen end stimulates the lacrimal ductule tissue easily, causes local damage and inflammation; Another kind of degradable embolus material is collagen protein, and about one all degradables put it into and can be used to judge whether the patient exists the tear phenomenon of overflowing after lacrimal ductule stops up lacrimal passage.

Summary of the invention:

The purpose of this utility model provides a kind of lacrimal duct embolus simple in structure, easy to use, with low cost.

This utility model is implemented by the following technical programs:

Lacrimal duct embolus of the present utility model comprises the lacrimal duct embolus body, it is characterized in that, described lacrimal duct embolus body is the little spindle broad in the middle in two or its centre of lacrimal duct embolus body is cylindrical, and two ends are blunt round.

Described lacrimal duct embolus body is preferably Ti-Ni alloy or poly-lacrimal duct embolus body to the oxygen cyclohexane extraction, and the lacrimal duct embolus of being made by Ti-Ni alloy is a kind of permanent type lacrimal duct embolus; The poly-lacrimal duct embolus that the oxygen cyclohexane extraction is made is a kind of half a year of soluble lacrimal duct embolus.

Preferably be provided with some axial notches at described lacrimal duct embolus body surface, further preferred, described axial notch is 4 ~ 10, is evenly distributed on this external surface of lacrimal duct embolus.Axial notch can make the tear of accumulation pass through, and avoids the lacrimal passage total blockage, causes canaliculitis and epiphora thereby avoid infection.

Lacrimal duct embolus of the present utility model is designed to the little spindle broad in the middle in two or its centre of lacrimal duct embolus body is cylindrical, two ends are blunt round, the lacrimal duct embolus of this shape, the slightly little and blunt circle of head and afterbody is smooth, fill in easily and arrive the target location in the lacrimal passage, stop up lacrimal ductule, and without sharp section, can not damage local organization and cause tissue inflammation.The structure of lacrimal duct embolus of the present utility model is very simple, and cost of manufacture is cheap, and general public can both afford to consume.

Description of drawings:

Fig. 1 is the horizontal sectional drawing of the lacrimal duct embolus of embodiment 1,

Wherein 1, lacrimal duct embolus body; 3, axial notch;

Fig. 2 is the horizontal sectional drawing of the lacrimal duct embolus of embodiment 2;

Wherein 2, lacrimal duct embolus body; 4, axial notch.

The specific embodiment:

Below be to further specify of the present utility model, rather than to restriction of the present utility model.

Embodiment 1:

As shown in Figure 1, the lacrimal duct embolus of present embodiment comprises poly-lacrimal duct embolus body 1 to oxygen cyclohexane extraction material, and this lacrimal duct embolus body 1 is the little spindle broad in the middle in two, is provided with 4 axial notches 3 on described lacrimal duct embolus body 1 surface.

Embodiment 2

As shown in Figure 2, the lacrimal duct embolus of present embodiment comprises the lacrimal duct embolus body 2 of Ti-Ni alloy, and the centre of this lacrimal duct embolus body 2 is cylindrical, and two ends are blunt round, are provided with 4 axial notches 4 on described lacrimal duct embolus body 2 surfaces.

Claims

1. a lacrimal duct embolus comprises the lacrimal duct embolus body, it is characterized in that, described lacrimal duct embolus body is the little spindle broad in the middle in two or its centre of lacrimal duct embolus body is cylindrical, and two ends are blunt round.

2. lacrimal duct embolus according to claim 1 is characterized in that, described lacrimal duct embolus body is Ti-Ni alloy or poly-lacrimal duct embolus body to the oxygen cyclohexane extraction.

3. lacrimal duct embolus according to claim 1 and 2 is characterized in that, is provided with some axial notches at described lacrimal duct embolus body surface.

4. lacrimal duct embolus according to claim 3 is characterized in that, described axial notch is 4 ~ 10, is evenly distributed on this external surface of lacrimal duct embolus.